Overview

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.
Phase:
Phase 3
Details
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Diagnosed with open angle glaucoma or ocular hypertension

- Provided signed, written informed consent

- 20 years of age and older

- If a subject is a female of childbearing potential, she must utilize reliable
contraceptive throughout the study, and must have a negative urine pregnancy test
prior to enrollment into this study

Exclusion Criteria:

- Females who are pregnant, nursing or planning a pregnancy, or females of childbearing
potential who are not using a reliable method of contraception.

- Presence of any abnormality or significant illness that could be expected to interfere
with the study.